Results 181 to 190 of about 46,900 (298)

Effects of Glucagon‐Like Peptide‐1 Receptor Agonists (Mono and Combination Therapy) on Energy Expenditure: A Scoping Review

open access: yesObesity Reviews, EarlyView.
ABSTRACT Introduction Weight loss results in reduced energy expenditure (EE) due to body composition alterations (e.g., fat‐free mass and fat mass losses) and mass‐independent adaptations in EE (e.g., hormones). Glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) are indicated for obesity management; however, their effects on EE remain unclear ...
Flavio T. Vieira   +8 more
wiley   +1 more source

Association of Glucagon‐Like Peptide‐1 Receptor Agonists and Suicidality: A Systematic Review

open access: yesObesity Reviews, EarlyView.
ABSTRACT Introduction Increased risk of suicidality has been reported in association with glucagon‐like peptide receptor agonist (GLP‐1 RA) prescription. Herein, we conducted a comprehensive review evaluating reports of GLP‐1 RA prescription and suicidality.
Hezekiah C. T. Au   +9 more
wiley   +1 more source

GLP‐1 Receptor Agonists and Weight Loss: A Critical Review of Mechanisms

open access: yesObesity Reviews, EarlyView.
ABSTRACT GLP‐1 receptor agonist medications have the potential to promote marked weight loss, but maximal and sustained benefit may be compromised by poor compliance and cessation of use. Development of next‐generation medications that address current obstacles to effective use and development of effective adjunct treatments will benefit from better ...
Giorgia Rutigliani   +8 more
wiley   +1 more source

Drug‐Induced Sialolithiasis—A Big‐Data Retrospective Study

open access: yesOral Diseases, EarlyView.
ABSTRACT Background Sialolithiasis pathophysiology is multifactorial, with systemic medications often hypothesised as a key contributor, particularly in older adults (Drug‐Induced Sialolithiasis). However, robust evidence supporting this theory is limited.
Gal Avishai   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy